目的：观察艾愈胶囊治疗卵巢癌的疗效和药物经济学情况。方法：选择2007年11月—2012年11月收治的卵巢癌患者120例，以随机数字表法分为治疗组60例、对照组60例。治疗组患者采用艾愈胶囊辅助治疗，对照组患者使用安慰剂辅助化疗。观察2组患者治疗后的临床疗效、安全性，并采用成本-效果分析模型进行药物经济学分析。结果：治疗组患者总有效率为90.0％（54／60），对照组为73.3％（44／60），2组差异有统计学意义（P＜0.05）；治疗后，治疗组仅9例患者出现不良事件，明显优于对照组的21例，2组差异有统计学意义（P＜0.05）；治疗组的成本-效果比为40.57，对照组为46.73，2组差异有统计学意义（P＜0.05）。结论：艾愈胶囊辅助化疗治疗卵巢癌安全、有效、经济，是相对合理的治疗药物，值得推广应用。%OBJECTIVE:To evaluate the curative efficacy and pharmacoeconomics of Aiyu capsule in treatment of ovarian cancer.METHODS:120 patients with ovarian cancer treated in our hosptial between Nov.2007 and Nov. 2011 were randomly assigned to receive chemotherapy plus either Aiyu capsule as adjuvant therapy ( experimental group) or placebo ( control group) , of 60 cases each.The efficacy and safety in the two groups were followed and the pharmacoeconomics in the two groups was evaluated using cost-effectiveness model.RESULTS:The total effective rate of the experimental group was 90%, as compard with 73.3%of the control group, and the difference was statistically significant between the two groups ( P<0.05 ) .Adverse events were noted in 9 cases of the experimental group versus 21 of the control group, and the difference between the two groups was statistically significant ( P<0.05) .The cost-effectiveness ratio was 40.57 for the experimental group as against 46.73 for the control group, and the difference between the two groups was statistically significant ( P<0.05 ) .CONCLUSIONS:Aiyu capsule added to chemotherapy was proved to be a safe, effective, economical and rational adjuvant therapy in treatment of ovarian cancer, which thus is worth of clinical recommendation.
展开▼
